TITLE

Consumer Usage Patterns of Nonprescription Histamine2-Receptor Antagonists

AUTHOR(S)
Chih-Wen Shi; Gralnek, Ian M.; Dulai, Gareth S.; Towfigh, Ali; Asch, Steven
PUB. DATE
April 2004
SOURCE
American Journal of Gastroenterology;Apr2004, Vol. 99 Issue 4, p606
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: Prescription to over-the-counter (OTC) drug switches are increasingly common. Yet little is known about how the public uses these reclassified products. Histamine2-receptor antagonists (H2RAs) are popular examples, although they may be supplanted by OTC proton pump inhibitors (PPIs). We examined the extent to which consumers substitute OTC H2RAs for physician care and/or engage in off-label use of these medications.METHODS: Self-administered anonymous survey of 1,116 adult OTC H2RA consumers in a random sample of 20 Los Angeles pharmacies from a major retail chain. Off-label use was defined by FDA warning label (e.g., bloody stools, dysphagia). Substitution was defined by intent to use H2RA instead of going to a physician.RESULTS: Forty-six percent engaged in off-label use of OTC H2RAs. Off-label use was independently associated with lower income, substitution for physician care, prior gastrointestinal disease, and past prescription H2RA use. Thirty-four percent substituted OTC H2RA use for physician care, and 54% of these met the criteria for off-label use. Substitution was associated with lack of health insurance, lack of time to see a physician, the belief that OTC H2RA was cheaper than clinic visits, and nonwhite race.CONCLUSION: Almost one-half of adult consumers reported using OTC H2RAs in a manner inconsistent with FDA labeling, and this off-label use was associated with substitution for physician care. Traditionally vulnerable populations were more prone to off-label use and to substituting H2RAs for physician care. Further studies are needed to assess patient outcomes, identify remedies, and explore implications for the reclassification of PPIs.
ACCESSION #
14816804

 

Related Articles

  • Gastric Acid Suppression by Proton Pump Inhibitors as a Risk Factor for Clostridium Difficile-Associated Diarrhea in Hospitalized Patients. Aseeri, Mohammed; Schroeder, Todd; Kramer, Joan; Zackula, Rosalee // American Journal of Gastroenterology;Sep2008, Vol. 103 Issue 9, p2308 

    BACKGROUND: Evidence for the association between Clostridium difficile ( C. difficile) and the use of proton pump inhibitor (PPI) is unclear. This study investigated the relationship between Clostridium difficile-associated diarrhea (CDAD) and exposure to acid suppressive therapy in hospitalized...

  • “Proton-pump inhibitor-first” strategy versus “step-up” strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. Habu, Yasuki; Maeda, Kazuo; Kusuda, Takeo; Yoshino, Takuya; Shio, Seiji; Yamazaki, Maki; Hayakumo, Takanobu; Hayashi, Kyohei; Watanabe, Yoshiyuki; Kawai, Keiichi // Journal of Gastroenterology;Nov2005, Vol. 40 Issue 11, p1029 

    Background. Gastroesophageal reflux disease (GERD) is a common condition, and acid-suppressing agents are the mainstays of treatment. For the acute medical management of GERD, two different strategies can be proposed: either the most effective therapy, i.e., protonpump inhibitors (PPIs), can be...

  • Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Marshall, John K.; Grootendorst, Paul V.; O'Brien, Bernie J.; Dolovich, Lisa R.; Holbrook, Anne M.; Levy, Adrian R. // CMAJ: Canadian Medical Association Journal;6/25/2002, Vol. 166 Issue 13, p1655 

    Abstract Background: Two programs to reduce expenditures for common gastrointestinal drugs were introduced simultaneously by British Columbia (BC) Pharmacare in 1995. Reference-based pricing restricted reimbursement for all histamine-2 receptor antagonists (H[sub2]RAs) to the cost of the least...

  • Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD. Brian Jacobson // Digestive Diseases & Sciences;Sep2008, Vol. 53 Issue 9, p2313 

    Abstract  In studies of the association between obesity and gastroesophageal reflux, one subject that has received very little attention is the effect excess body mass may have on the effectiveness of acid-mediating agents. The lack of systematic research may reflect the perceived high...

  • Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review. Mitsushige Sugimoto; Jin Seok Jang; Yashiro Yoshizawa; Satoshi Osawa; Ken Sugimoto; Yoshihiko Sato; Takahisa Furuta // Diagnostic & Therapeutic Endoscopy;2012, p1 

    Endoscopic submucosal dissection (ESD) is a novel endoscopic procedure first developed in the 1990s which enables en bloc resection of gastric neoplastic lesions that are difficult to resect via conventional endoscopic mucosal resection. However, given that ESD increases the risk of intra- and...

  • A Prospective Randomized Trial of Esomeprazole- versus Pantoprazole-Based Triple Therapy for Helicobacter pylori Eradication. Ping-I Hsu; Kwok-Hung Lai; Chiun-Ku Lin; Wen-Chi Chen; Hsien-Chung Yu; Jin-Shiung Cheng; Feng-Woei Tsay; Chung-Jen Wu; Ching-Chu Lo; Hui-Hwa Tseng; Yoshio Yamaoka; Jin-Liang Chen; Gin-Ho Lo // American Journal of Gastroenterology;Nov2005, Vol. 100 Issue 11, p2387 

    OBJECTIVE: This prospective, randomized, controlled, head-to-head study was conducted to compare the efficacies of esomeprazole- and pantoprazole-based triple therapies for Helicobacter pylori eradication. METHODS: From January 2002 to October 2003, 200 H. pylori-infected patients were randomly...

  • Continuing Medical Education: July 2011.  // American Journal of Gastroenterology;Jul2011, Vol. 106 Issue 7, p1208 

    The article offers information on the continuing medical education (CME) activity designed for physicians in gastroenterology and hepatology on diagnostic gastrointestinal (GI) and state-of-the-art treatment of the illnesses. It states that the participants are expected to have bettered...

  • HAS PPI USE AFFECTED HOW CARCINOMAS PRESENT? Dixon, Andrew; de Caestecker, John // Pulse;5/25/2006, Vol. 66 Issue 21, p38 

    The article presents a question and its answer related to the use of proton pump inhibitors (PPIs). A person has asked about the impact of using PPIs. The use of PPIs can influence the presentation of upper gastrointestinal carcinomas. Various aspects of PPI treatment have been examined by...

  • Switch-up for the 'Purple Pill'.  // Drug Store News;8/25/2014, Vol. 36 Issue 8, p112 

    The article reports on the successful switching of Pfizer's Nexium proton pump inhibitors to over-the-counter in May 2014 which caused a $6 billion book prescription business to antacid aisles, according to a 2012 data from health care information provider IMS Health.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics